Identifying patients at risk for QT interval prolongation: Case studies

Journal of Family Practice

Volumn 54, Issue 6 SUPPL., 2005, Pages

  Flyer, Jack L ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CEFTRIAXONE; ERYTHROMYCIN; MOXIFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CASE REPORT; DEPRESSION; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS ADMINISTRATION; PATIENT MONITORING; PNEUMONIA; QT PROLONGATION; RESPIRATORY TRACT INFECTION; TORSADE DES POINTES; TREATMENT OUTCOME; ANAMNESIS; CHEMICALLY INDUCED DISORDER; LONG QT SYNDROME; METHODOLOGY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; FEMALE; FLUOROQUINOLONES; HUMANS; LONG QT SYNDROME; MEDICAL HISTORY TAKING; PNEUMONIA; RISK ASSESSMENT; RISK FACTORS;

EID: 20444392738     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Committee for Proprietary Medicinal Products (CPMP). The European Agency for the Evaluation of Medicinal Products. Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products. CPMP/986/96. 1997. Available at: http://www.emea.eu.int/pdfs/human/ swp/098696en.pdf. Accessed November 15, 2004.
2. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
3. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
4. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75:234-241.
5. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med.2004;351:1089-1096.